ArticleFrontiers in oncology2026
The RBP2-BECN1-VEGFA axis orchestrates a self-amplifying circuit to drive malignant progression in gastric carcinoma.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Gastric carcinoma (GC) is a leading cause of cancer-related mortality, often driven by epigenetic dysregulation. This study investigates the role of Retinoblastoma-binding protein 2 (RBP2), a chromatin-associated transcriptional regulator frequently overexpressed in GC. We specifically focus on elucidating how RBP2 functions as a transcriptional regulator within the autophagy-angiogenesis network and its impact on disease progression. Methods: The regulatory axis was dissected using integrated approaches, including transcriptomic profiling, cellular and molecular biology assays, and Results: We discovered that RBP2 drives GC progression by establishing an autophagy-angiogenesis positive feedback loop. RBP2 transcriptionally regulates BECN1 through promoter-dependent mechanisms supported by dual-luciferase reporter and ChIP-qPCR assays, thereby inducing protective autophagy. This autophagy enhances VEGFA secretion, which upregulates RBP2 via the inactivation of the JNK/p53/miR-212 axis, thereby relieving post-transcriptional repression. This self-reinforcing circuit facilitates sustained gastric carcinogenesis. Conclusion: Our findings support a novel "RBP2-BECN1 -VEGFA-JNK/p53/miR-212-RBP2" regulatory axis that links epigenetic regulation to autophagic survival and angiogenic signaling. This study elucidates a key mechanism underlying GC pathogenesis and suggests potential targets for combinatorial therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.